...let's not to get too far ahead of ourselves...Siga's current pipeline hopefuls have been targeting mainly viruses with brief mention on some anti-sortase drugs targeting bacterias advancing to the preclinical stages. Although there was some talk about this noval application of these drugs, it still has a long way yet on the antibacterial front development. SORTASE: SIGA has identified the critical role of sortase, an enzyme that is part of the pathogenesis of Gram-positive bacteria. In developing an agent to inhibit sortase, SIGA has discovered a way to prevent such bacteria from colonizing and causing disease. SIGA’s sortase anti-bacterial is intended to be effective against Gram-positive bacterial pathogens, including Staphylococcus aureus, Streptococcus pyogenes, Enterococcus faecalis, Streptococcus pneumoniae, and resistant derivatives. A sortase anti-bacterial could also be administered against biodefense targets such as Bacillus anthracis, Clostridium botulinum, and Listeria monocytogenes. SIGA has identified several series of compounds that have shown potent in vitro activity against sortase. SIGA is now in the process of advancing them to the preclinical stage
I believe SIGA does have an anthrax drug that could be a potential candidate. It was put on the back burner with small pox ST-246 the primary focus. Perhaps we have another potential revenue stream in the future.